02.05.2023 22:18:54
|
Sarepta Therapeutics Q1 Loss Increases, but beats estimates
(RTTNews) - Sarepta Therapeutics (SRPT) revealed Loss for its first quarter that increased from last year and missed the Street estimates.
The company's earnings came in at -$516.76 million, or -$5.86 per share. This compares with -$105.03 million, or -$1.20 per share, in last year's first quarter.
Excluding items, Sarepta Therapeutics reported adjusted earnings of -$85.50 million or -$0.97 per share for the period.
Analysts on average had expected the company to earn -$1.38 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 20.2% to $253.50 million from $210.83 million last year.
Sarepta Therapeutics earnings at a glance (GAAP) :
-Earnings (Q1): -$516.76 Mln. vs. -$105.03 Mln. last year. -EPS (Q1): -$5.86 vs. -$1.20 last year. -Analyst Estimate: -$1.38 -Revenue (Q1): $253.50 Mln vs. $210.83 Mln last year.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sarepta Therapeutics Inc.mehr Nachrichten
05.11.24 |
Ausblick: Sarepta Therapeutics präsentiert Quartalsergebnisse (finanzen.net) | |
21.06.24 |
Sarepta Therapeutics-Aktie mit Kurssprung: Roche-Partner erhält FDA-Zulassung für Medikament gegen Muskelschwund (finanzen.at) |